“Complete Response” Reg Proposes Deficiency Letter For Withdrawn NDAs
This article was originally published in The Tan Sheet
Executive Summary
The definition of an efficacy supplement, which covers Rx-to-OTC switch applications, would be written into regulation for the first time under a new proposed rule issued by FDA
You may also be interested in...
FDA Rejects “Not Approvable” Letters, Clarifies Efficacy Supplement
FDA says industry concerns about the implied finality of "not approvable" letters led it to change how it responds to drug applications
FDA Rejects “Not Approvable” Letters, Clarifies Efficacy Supplement
FDA says industry concerns about the implied finality of "not approvable" letters led it to change how it responds to drug applications
FDA Rejects “Not Approvable” Letters, Clarifies Efficacy Supplement
FDA says industry concerns about the implied finality of "not approvable" letters led it to change how it responds to drug applications